# US Preimplantation Genetic Testing Market

> US Preimplantation Genetic Testing Market Research Report: Size, Share, Trend Analysis By Applications (Diagnostic Testing, Carrier Screening, Embryo Selection), By Technique (Polymerase Chain Reaction, Next Generation Sequencing, Fluorescence In Situ Hybridization, Single Nucleotide Polymorphism), By End Use (Fertility Clinics, Research Laboratories, Hospitals) and By Client Type (Individuals, Healthcare Providers, Healthcare Institutions) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.03%
- **2024:** $ 450 Million
- **2025:** $ 481.63 Million
- **2035:** $ 950 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Fulgent Genetics (US), Natera (US), CooperSurgical (US), PreventionGenetics (US), Genea (AU), Reproductive Health Technologies (US)

**Report ID:** MRFR/MED/13083-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-preimplantation-genetic-testing-market-14610

---

## Market Summary

## **US Preimplantation Genetic Testing Market Overview**

As per MRFR analysis, the US Preimplantation Genetic Testing Market Size was estimated at 413.7 (USD Million) in 2023. The US Preimplantation Genetic Testing Market Industry is expected to grow from 443.1(USD Million) in 2024 to 945 (USD Million) by 2035. The US Preimplantation Genetic Testing Market CAGR (growth rate) is expected to be around 7.128% during the forecast period (2025 - 2035).

### **Key US Preimplantation Genetic Testing Market Trends Highlighted**

The US Preimplantation Genetic Testing Market is experiencing notable trends driven by various societal and technological factors. One key market driver is the growing awareness and acceptance of genetic testing among prospective parents, driven largely by educational initiatives and advancements in reproductive health technologies. The increase in demand for in-vitro fertilization (IVF) procedures further fuels the need for preimplantation genetic testing, as these tests help identify potential genetic disorders in embryos, ensuring healthier outcomes for pregnancies. Additionally, insurance coverage policies in several states support this trend by making genetic testing more affordable for patients, thereby promoting its adoption.

Opportunities to be explored in this market include the expansion of genetic testing services to a broader demographic. With rising health consciousness and increasing focus on personalized medicine, integrating [preimplantation genetic testing](../../../reports/preimplantation-genetic-testing-market-8121) into broader maternal health initiatives could enhance service reach and accessibility. Furthermore, advancements in artificial intelligence and machine learning have the potential to improve diagnostic capabilities, making testing more reliable and efficient, which is an area that can be leveraged for growth.

Recent trends also indicate that there is a push towards more informed decision-making processes among patients regarding their reproductive choices. Dialogue on genetic health is becoming more prevalent, leading to increased consultations around preimplantation genetic testing. Innovations in testing methods and the development of non-invasive techniques are likely to enhance the user experience and offer more options for patients. Overall, as the landscape evolves, there is a clearer alignment between consumer demand and technological advancements that are shaping the future of the Preimplantation Genetic Testing Market in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Preimplantation Genetic Testing Market Drivers**

### **Rising Awareness of Genetic Disorders**

The increasing awareness regarding genetic disorders in the United States is a prominent driver for the US Preimplantation Genetic Testing Market Industry. With a shift towards preventive healthcare, many prospective parents are seeking testing to understand their genetic risks. According to the Centers for Disease Control and Prevention (CDC), about 1 in 33 babies is born with a birth defect, highlighting the necessity for genetic testing options like Preimplantation Genetic Testing to mitigate risks.

Organizations such as the National Society of Genetic Counselors (NSGC) are playing a key role by providing educational resources, thereby promoting awareness and increasing demand for genetic testing services. This growing awareness not only aids patients in making informed reproductive choices but also fuels market growth in the US preimplantation genetic testing sector.

### **Advancements in Genetic Testing Technology**

Technological advancements in genetic testing are significantly influencing the US Preimplantation Genetic Testing Market Industry. With the rapid evolution of techniques such as next-generation sequencing and array comparative genomic hybridization, more precise and quicker results are achievable. The American College of Obstetricians and Gynecologists (ACOG) has noted that these advancements improve the reliability of genetic testing, enabling clinicians to detect genetic anomalies more effectively.

As technology continues to advance, it is expected that the scope and accuracy of preimplantation genetic tests will expand, leading to higher adoption rates among fertility clinics across the United States.

### **Increase in Adoption of Assisted Reproductive Technologies**

The growing use of Assisted Reproductive Technologies (ART) in the US is a critical driver for the US Preimplantation Genetic Testing Market Industry. According to the Society for Assisted Reproductive Technology (SART), more than 330,000 ART cycles were performed in the United States in 2020, with a notable percentage of these involving preimplantation genetic testing. This trend can be attributed to increasing infertility rates and changing societal attitudes toward family planning.

As more individuals opt for ART, the integration of preimplantation genetic testing is becoming a standard practice to ensure healthier outcomes for neonates, driving substantial growth in the market.

### **Legislative Support for Genetic Testing**

The legislative landscape in the United States has become increasingly supportive of genetic testing initiatives, positively impacting the US Preimplantation Genetic Testing Market Industry. Various states have enacted laws aimed at expanding insurance coverage for genetic testing, thereby making these services more accessible to a broader population. For instance, the Genetic Information Nondiscrimination Act (GINA) provides protection against discrimination based on genetic information, which minimizes the uncertainty surrounding genetic testing for prospective parents.

Support from government policies has a favorable impact on market growth as it facilitates wider acceptance and utilization of preimplantation genetic testing, paving the way for a more robust industry landscape.

## **US Preimplantation Genetic Testing Market Segment Insights**

### **Preimplantation Genetic Testing Market Application Insights**

The US Preimplantation Genetic Testing Market undergoes substantial transformation, particularly within the Application segment, which encompasses Diagnostic Testing, Carrier Screening, and Embryo Selection. Diagnostic Testing plays a pivotal role, facilitating early identification of genetic disorders or chromosomal abnormalities, thereby guiding couples in their reproductive decisions. This aspect is crucial as it allows parents to make informed choices regarding embryo selection, prioritizing healthier genetic profiles.

In Carrier Screening, advancements aim to identify potential carriers of genetic conditions, enabling proactive measures in family planning. This practice is gaining momentum as awareness increases regarding genetic conditions prevalent among various populations in the US, making it a key consideration for couples planning to conceive.

Embryo Selection, another significant component of this market segment, underscores the science of selecting embryos with the highest likelihood of successful implantation and healthy development. This precision not only enhances chances for successful pregnancies but also reduces the emotional and financial burden associated with infertility treatments.

The growing trend towards personalized medicine further accentuates the importance of these applications as patients increasingly seek targeted genetic insights tailored to their familial backgrounds. The US Preimplantation Genetic Testing Market is expected to see expanded adoption of these applications due to a combination of rising fertility rates, technological advancements, and increasing public awareness of genetic health issues. Furthermore, regulatory support and improvements in healthcare accessibility are anticipated to foster continued growth, paving the way for enhanced reproductive health outcomes across various demographics in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Preimplantation Genetic Testing Market Technique Insights**

The US Preimplantation Genetic Testing Market is characterized by various techniques that play a crucial role in advancing reproductive genetics. Among these techniques, Polymerase Chain Reaction (PCR) is recognized for its rapid amplification of DNA, making it essential for detecting genetic disorders at early stages.

Next Generation Sequencing (NGS) has gained prominence due to its ability to provide comprehensive genetic profiling, allowing for the identification of multiple genetic conditions simultaneously, thus streamlining the testing process. Fluorescence In Situ Hybridization (FISH) offers precise visualization of chromosomes, making it invaluable in diagnosing chromosomal abnormalities during preimplantation stages.

Additionally, Single Nucleotide Polymorphism (SNP) analysis aids in understanding genetic variations relevant to hereditary diseases. Together, these technologies enhance the accuracy and reliability of preimplantation genetic testing, offering families informed choices in reproductive health. The ongoing advancements and integration of these techniques are expected to substantially impact the growth trajectory of the US Preimplantation Genetic Testing Market, with rising awareness and increasing investments in Research and Development driving innovation and accessibility in genetic testing services.

### **Preimplantation Genetic Testing Market End Use Insights**

The US Preimplantation Genetic Testing Market focuses on key End Use sectors, including Fertility Clinics, Research Laboratories, and Hospitals, each playing a critical role in the adoption and implementation of genetic testing technologies. Fertility Clinics dominate this segment as they provide essential services to couples undergoing in-vitro fertilization, benefiting from advancements in genetic testing to improve success rates and reduce the risk of genetic disorders.

Research Laboratories contribute significantly by driving innovation and developing new techniques, often leading to breakthroughs in Preimplantation Genetic Testing methods. Hospitals also serve a vital function, integrating genetic testing into broader patient care pathways, enabling more personalized treatment options.

The collaborative efforts among these segments reflect the growing trend toward personalized medicine, utilizing Preimplantation Genetic Testing to enhance reproductive outcomes. Furthermore, increasing awareness, advancements in technology, and supportive policies contribute to market growth in these areas, presenting ample opportunities for development and collaboration within the US Preimplantation Genetic Testing Market.

### **Preimplantation Genetic Testing Market Client Type Insights**

The Client Type segment of the US Preimplantation Genetic Testing Market reveals critical insights into the diverse groups that utilize these genetic testing services. Individuals, representing prospective parents primarily concerned with hereditary conditions, form a significant part of the market, driving the need for efficient preimplantation genetic testing solutions.

Healthcare Providers, including specialists and clinicians, play an essential role by recommending genetic testing as part of fertility treatments, which heightens patient awareness and demand. Meanwhile, Healthcare Institutions such as hospitals and fertility clinics are crucial in offering these services on a broader scale, enabling access to advanced diagnostic capabilities.

With an increasing focus on personalized medicine and advancements in reproductive technologies, this segment showcases a growing trend towards comprehensive genetic screening as part of reproductive planning. The ongoing evolution of genetic testing methodologies and patient education also drives significant growth within the Client Type categorizations, indicating a promising future for the industry. The interplay of these groups illustrates a dynamic ecosystem where awareness, accessibility, and advancements in technology enhance the overall landscape of genetic testing in the US.

## **US Preimplantation Genetic Testing Market Key Players and Competitive Insights**

The US Preimplantation Genetic Testing Market is characterized by a dynamic landscape shaped by technological advancements, growing consumer awareness of genetic disorders, and increasing acceptance of assisted reproductive technologies. This market is witnessing significant competition among key players who are developing innovative solutions aimed at enhancing the accuracy and efficiency of preimplantation genetic diagnosis and testing. The increasing prevalence of genetic abnormalities and the rising demand for in vitro fertilization have catalyzed market growth, resulting in a wave of investments that focus on research and development.

Market participants are vying for a competitive edge by forging strategic partnerships, enhancing their product portfolios, and expanding their service offerings to capture a larger share of this burgeoning market. As advancements in genomics continue to evolve, the competitive landscape will likely continue to become more intricate, with new players emerging and established companies consolidating their positions.

Illumina stands out prominently in the US Preimplantation Genetic Testing Market due to its robust technological capabilities and extensive product portfolio. The company specializes in next-generation sequencing technologies, enabling high-throughput genetic analyses that are critical for the accurate diagnosis of preimplantation genetic conditions. Illumina's strong reputation in the genomics space helps in establishing credibility among healthcare providers and patients alike. The company’s significant investments in research and development bolster its competitive advantage, allowing it to stay ahead in a rapidly evolving market.

Illumina’s continuous efforts to innovate have led to the introduction of advanced solutions that cater to the needs of fertility clinics and reproductive specialists, further embedding its presence in the US market. The company has strategically positioned itself through collaborations with fertility clinics and researchers, enhancing its visibility and reinforcing its status as a leader in preimplantation genetic testing.

LabCorp also plays a pivotal role in the US Preimplantation Genetic Testing Market, offering a comprehensive range of genetic testing services. The company is recognized for its extensive laboratory network and commitment to providing accurate and timely testing solutions. LabCorp’s portfolio includes key services related to preimplantation genetic testing, with the integration of cutting-edge technologies that enhance diagnostic capabilities. The firm's strong presence across the US healthcare landscape is supported by strategic mergers and acquisitions, allowing it to expand its geographical reach and strengthen its service offerings in reproductive health.

LabCorp’s established relationships with healthcare providers and its commitment to quality assurance resonate with both clinicians and patients, reinforcing its market position. The integration of advanced methodologies in genetic analysis sets LabCorp apart, ensuring that it remains competitive as technology progresses within the realm of preimplantation genetic testing.

### **Key Companies in the US Preimplantation Genetic Testing Market Include**

- Illumina
- LabCorp
- Fulgent Genetics
- Genomic Health
- Myriad Genetics
- PerkinElmer
- Thermo Fisher Scientific
- Sema4
- Quest Diagnostics
- Roche
- Cleveland Clinic
- Invitae
- **[CooperSurgical](https://www.coopersurgical.com/products/?specialty=fertility-and-birth&category=assisted-reproductive-tech&product_type=reproductive-genetic-testing)**
- Natera

## **US Preimplantation Genetic Testing Market Industry Developments**

The US Preimplantation Genetic Testing Market has witnessed significant developments recently, particularly with advancements in technology and genetic testing services. Companies like Illumina and Thermo Fisher Scientific continue to enhance their offerings in next-generation sequencing, impacting the market positively. LabCorp and Quest Diagnostics are ramping up their genetic screening services in response to increased consumer demand for personalized medicine.

In terms of mergers and acquisitions, in September 2023, Illumina completed its acquisition of GRAIL, enhancing its capabilities in multi-cancer early detection, which strengthens its position in the preimplantation testing space. Additionally, in July 2023, Myriad Genetics announced its acquisition of Sema4’s GenomeFirst platform, expanding its portfolio in genetic testing.

The increasing prevalence of genetic disorders and rising awareness among patients have driven market growth, with genetic testing becoming a crucial part of assisted reproductive technology. Moreover, the US witnessed a notable increase in investment in companies like Natera and CooperSurgical, emphasizing Research and Development initiatives in genetic testing. Overall, the landscape of the US Preimplantation Genetic Testing Market is rapidly evolving, reflecting the growing importance of genetic insights in reproductive health.

## **US Preimplantation Genetic Testing Market Segmentation Insights**

### **Preimplantation Genetic Testing Market Application Outlook**

- Diagnostic Testing
- Carrier Screening
- Embryo Selection

### **Preimplantation Genetic Testing Market Technique Outlook**

- Polymerase Chain Reaction
- Next Generation Sequencing
- Fluorescence In Situ Hybridization
- Single Nucleotide Polymorphism

### **Preimplantation Genetic Testing Market End Use Outlook**

- Fertility Clinics
- Research Laboratories
- Hospitals

### **Preimplantation Genetic Testing Market Client Type Outlook**

- Individuals
- Healthcare Providers
- Healthcare Institutions

## Market Drivers

### Rising Infertility Rates

The increasing prevalence of infertility in the US is a notable driver for the preimplantation genetic-testing market. Factors such as delayed childbearing, lifestyle choices, and environmental influences contribute to this trend. According to the CDC, approximately 12 % of women aged 15-44 experience difficulty in conceiving, which has led to a heightened interest in assisted reproductive technologies. As couples seek solutions, the demand for preimplantation genetic testing rises, as it offers a way to identify genetic disorders before implantation. This growing need for effective reproductive solutions is likely to propel the market forward, as more individuals and couples turn to genetic testing to enhance their chances of successful pregnancies.

### Increased Insurance Coverage

The expansion of insurance coverage for preimplantation genetic testing is a crucial driver for the market. Many insurance providers are beginning to recognize the value of genetic testing in reducing long-term healthcare costs associated with genetic disorders. As more policies include coverage for these services, patients are more likely to pursue preimplantation genetic testing as part of their fertility treatment plans. This shift not only alleviates the financial burden on couples but also encourages wider adoption of genetic testing services. The preimplantation genetic-testing market is expected to benefit from this trend, as increased insurance coverage may lead to a higher number of patients seeking these essential services.

### Advancements in Genetic Technologies

Technological innovations in genetic testing methodologies are significantly impacting the preimplantation genetic-testing market. The introduction of next-generation sequencing (NGS) and improved bioinformatics tools has enhanced the accuracy and efficiency of genetic testing. These advancements allow for comprehensive analysis of embryos, enabling the identification of genetic abnormalities with greater precision. As a result, fertility clinics are increasingly adopting these technologies to provide better outcomes for patients. The market is projected to grow as these technologies become more accessible and affordable, potentially increasing the number of clinics offering preimplantation genetic testing services. This trend indicates a shift towards more personalized reproductive healthcare.

### Growing Awareness of Genetic Disorders

The rising awareness of genetic disorders among the US population is driving the preimplantation genetic-testing market. Educational campaigns and advocacy groups have played a pivotal role in informing individuals about the risks associated with genetic conditions. As more people become aware of the potential for hereditary diseases, they are increasingly inclined to seek genetic testing options during their reproductive journeys. This heightened awareness not only influences individual decisions but also encourages healthcare providers to offer preimplantation genetic testing as a standard part of fertility treatments. Consequently, the market is likely to experience growth as more couples opt for testing to ensure healthier pregnancies.

### Regulatory Support for Genetic Testing

Regulatory frameworks in the US are evolving to support advancements in the preimplantation genetic-testing market. Agencies such as the FDA are working to establish guidelines that ensure the safety and efficacy of genetic testing technologies. This regulatory support fosters innovation and encourages the development of new testing methods. As regulations become more favorable, companies in the preimplantation genetic-testing market may find it easier to introduce novel products and services. This environment of regulatory encouragement is likely to stimulate market growth, as it enhances consumer confidence in the safety and reliability of genetic testing.

## Future Outlook

The [Preimplantation Genetic Testing Market](https://www.marketresearchfuture.com/reports/preimplantation-genetic-testing-market-8121) is projected to grow at a 7.03% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising demand for personalized medicine.

**New opportunities:**

- Development of AI-driven genetic analysis platforms
- Expansion of telehealth services for genetic counseling
- Partnerships with fertility clinics for integrated testing solutions

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Diagnostic Testing (Largest) vs. Carrier Screening (Fastest-Growing)

In the US preimplantation genetic-testing market, Diagnostic Testing holds the largest market share among the application segment values. It serves as the foundational pillar for ensuring embryo viability and genetic health, catering to a wide range of genetic disorders. On the other hand, Carrier Screening, while smaller in market share, is rapidly gaining traction due to increasing awareness and demand for personalized medicine, making it a vital contender in this space.

Growth trends indicate a significant shift towards the integration of advanced technologies in the US preimplantation genetic-testing market. The rising prevalence of genetic disorders, coupled with enhancements in testing methodologies, drives the demand for both Diagnostic Testing and Carrier Screening. This growth is further fueled by the increasing emphasis on reproductive health and the desire for informed family planning, making it a dynamic segment poised for expansion.

Diagnostic Testing: Dominant vs. Carrier Screening: Emerging

Diagnostic Testing remains the dominant application in the US preimplantation genetic-testing market due to its critical role in assessing embryo viability and identifying potential genetic abnormalities. It caters to a diverse population, ensuring successful pregnancies through a thorough analysis of genetic health. In contrast, Carrier Screening is an emerging application that focuses on identifying individuals who carry gene mutations for specific diseases. As personalized healthcare becomes more prevalent, the interest in Carrier Screening is escalating, driven by advancements in technology and a shift towards proactive health management. This dual application landscape showcases a robust market structure where established methodologies coalesce with innovative practices to enhance reproductive outcomes.

### By Technique: Polymerase Chain Reaction (Largest) vs. Next Generation Sequencing (Fastest-Growing)

In the US preimplantation genetic-testing market, the technique segment has seen a varied distribution of market share among its key players. Polymerase Chain Reaction (PCR) has established itself as the largest technique utilized, owing to its robustness and efficiency in amplifying DNA segments. Meanwhile, Next Generation Sequencing (NGS) is emerging as a significant force, rapidly gaining traction due to its capability for high-throughput analysis and comprehensive genetic profiling.

The growth trends within this segment are driven by advancements in technology and increased demand for precise genetic analyses. PCR remains favored for its cost-effectiveness and established protocols, while NGS is noted for its ability to provide deeper insights into genetic conditions. As awareness of genetic disorders increases, both techniques are poised for significant growth, but with NGS leading in terms of innovation and adoption rates.

Technology: PCR (Dominant) vs. NGS (Emerging)

Polymerase Chain Reaction (PCR) stands out as the dominant technique in the US preimplantation genetic-testing market due to its effectiveness in amplifying specific DNA sequences, making it a reliable choice for genetic testing. Its established protocols have made it an integral part of many laboratories. On the other hand, Next Generation Sequencing (NGS) is recognized as an emerging technique that utilizes advanced technologies to sequence multiple genes simultaneously, providing a broader understanding of genetic information. NGS is particularly appealing for its rapid turnaround time and the depth of data it offers, allowing practitioners to make more informed decisions regarding genetic conditions. This dynamic interplay between PCR and NGS illustrates the diverse needs within the market, catering to both established practices and cutting-edge innovations.

### By End Use: Fertility Clinics (Largest) vs. Research Laboratories (Fastest-Growing)

The US preimplantation genetic-testing market exhibits a diverse distribution of end-use segments, with Fertility Clinics commanding the largest share due to their critical role in assisted reproductive technologies. These facilities leverage genetic testing to ensure healthy pregnancies, driving high demand for preimplantation assessments. Research Laboratories are increasingly carving out significant market presence as they develop innovative genetic testing methodologies, reflective of the growing emphasis on research-driven healthcare solutions.

In terms of growth trends, Research Laboratories are identified as the fastest-growing segment, fueled by advancements in technology and the increasing importance of genetic screening in personalized medicine. The drive for improved success rates in fertility treatments is pushing fertility clinics to adopt more sophisticated genetic tests, while research institutions are continually enhancing their capabilities. This dynamic interplay between end users is essential for the evolution of genetic testing practices in reproductive health.

Fertility Clinics (Dominant) vs. Research Laboratories (Emerging)

Fertility Clinics play a dominant role in the US preimplantation genetic-testing market, providing essential services to couples seeking to optimize their chances of healthy pregnancies. These clinics utilize cutting-edge genetic technologies to perform comprehensive screenings, ensuring the identification of viable embryos and avoiding genetic disorders. On the other hand, Research Laboratories are emerging as crucial players, focusing on innovation and development of new genetic testing techniques. Their emphasis on research not only enhances the existing methodologies but also broadens the applications of genetic testing in various medical frameworks. Together, these segments reflect the critical balance between clinical practice and research advancement, shaping the future landscape of genetic testing in reproductive health.

### By Client Type: Healthcare Providers (Largest) vs. Individuals (Fastest-Growing)

In the US preimplantation genetic-testing market, the distribution of market share among the client types shows that healthcare providers hold the largest segment, benefitting from established protocols and integration into existing healthcare systems. On the other hand, individuals represent a rapidly growing segment as awareness and demand for personalized genetic services increase, driving more people to seek direct access to these technologies.

The growth trends within these segments are influenced by various factors. Healthcare providers continue to adopt advanced genetic testing solutions, enhancing their service offerings, while individuals are increasingly motivated by the desire for informed reproductive choices. The rise in genetic literacy and advancements in testing technology are key drivers pushing both segments forward, with individuals looking for more control over their genetic health decisions.

Healthcare Providers: Dominant vs. Individuals: Emerging

Healthcare providers in the US preimplantation genetic-testing market are positioned as the dominant client type, leveraging their established role in patient care and extensive networks within the healthcare ecosystem. Their ability to integrate genetic testing into broader health services makes them crucial players. Meanwhile, individuals are emerging as a significant force, fueled by a growing desire for personalized medicine and direct access to genetic information. This shift represents a transformative trend where consumers increasingly seek autonomy over their reproductive health, leading to greater advocacy for genetic testing innovations that cater directly to personal needs. As these dynamics continue to evolve, both segments will play pivotal roles in shaping the future landscape of genetic testing.

## Competitive Benchmarking

The preimplantation genetic-testing market is characterized by a dynamic competitive landscape, driven by advancements in genetic technologies and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Natera (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its genomic sequencing capabilities, while Thermo Fisher Scientific (US) emphasizes the integration of advanced analytics into its testing solutions. Natera (US) is strategically positioned through its robust data analytics platform, which supports its genetic testing services, thereby shaping a competitive environment that prioritizes technological advancement and customer-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Illumina (US) and Thermo Fisher Scientific (US) suggests a trend towards consolidation, as these firms seek to leverage economies of scale and broaden their service offerings.

In October  Illumina (US) announced a strategic partnership with a leading fertility clinic to enhance its preimplantation genetic testing services. This collaboration aims to integrate Illumina's advanced sequencing technology with the clinic's clinical expertise, potentially improving patient outcomes and expanding access to genetic testing. Such partnerships may signify a shift towards more integrated healthcare solutions, where technology and clinical practice converge.

In September  Natera (US) launched a new product line focused on non-invasive prenatal testing, which complements its existing preimplantation genetic testing offerings. This expansion into prenatal testing reflects Natera's commitment to broadening its genetic testing portfolio and addressing the growing consumer demand for comprehensive reproductive health solutions. The strategic importance of this move lies in its potential to capture a larger share of the reproductive health market, thereby enhancing Natera's competitive edge.

In August  Thermo Fisher Scientific (US) unveiled a new digital platform designed to streamline the genetic testing process for healthcare providers. This platform aims to enhance user experience and improve data management, which could lead to increased adoption of their testing services. The introduction of such digital solutions indicates a broader trend towards digital transformation within the industry, as companies seek to leverage technology to improve operational efficiency and customer engagement.

As of November  current competitive trends in the preimplantation genetic-testing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into testing processes. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized healthcare solutions.

## Recent News & Developments

The US Preimplantation Genetic Testing Market has witnessed significant developments recently, particularly with advancements in technology and genetic testing services. Companies like Illumina and Thermo Fisher Scientific continue to enhance their offerings in next-generation sequencing, impacting the market positively. LabCorp and Quest Diagnostics are ramping up their genetic screening services in response to increased consumer demand for personalized medicine.

In terms of mergers and acquisitions, in September 2023, Illumina completed its acquisition of GRAIL, enhancing its capabilities in multi-cancer early detection, which strengthens its position in the preimplantation testing space. Additionally, in July 2023, Myriad Genetics announced its acquisition of Sema4’s GenomeFirst platform, expanding its portfolio in genetic testing.

The increasing prevalence of genetic disorders and rising awareness among patients have driven market growth, with genetic testing becoming a crucial part of assisted reproductive technology. Moreover, the US witnessed a notable increase in investment in companies like Natera and CooperSurgical, emphasizing Research and Development initiatives in genetic testing. Overall, the landscape of the US Preimplantation Genetic Testing Market is rapidly evolving, reflecting the growing importance of genetic insights in reproductive health.

## Report Scope

| MARKET SIZE 2024 | 450.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 481.63(USD Million) |
| MARKET SIZE 2035 | 950.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.03% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Fulgent Genetics (US), Natera (US), CooperSurgical (US), PreventionGenetics (US), Genea (AU), Reproductive Health Technologies (US) |
| Segments Covered | Application, Technique, End Use, Client Type |
| Key Market Opportunities | Advancements in gene editing technologies enhance accuracy and accessibility in the preimplantation genetic-testing market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the preimplantation genetic-testing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US preimplantation genetic-testing market?**
A: The market valuation was $450.0 Million in 2024.

**Q: What is the projected market size for the US preimplantation genetic-testing market by 2035?**
A: The market is projected to reach $950.0 Million by 2035.

**Q: What is the expected CAGR for the US preimplantation genetic-testing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.03% during the forecast period.

**Q: Which companies are considered key players in the US preimplantation genetic-testing market?**
A: Key players include Illumina, Thermo Fisher Scientific, Fulgent Genetics, Natera, and CooperSurgical.

**Q: What are the main application segments in the US preimplantation genetic-testing market?**
A: Main application segments include Diagnostic Testing, Carrier Screening, and Embryo Selection.

**Q: What is the valuation range for the Diagnostic Testing segment in the US preimplantation genetic-testing market?**
A: The Diagnostic Testing segment ranges from $180.0 Million to $380.0 Million.

**Q: Which technique segment is expected to have the highest valuation in the US preimplantation genetic-testing market?**
A: Next Generation Sequencing is expected to have the highest valuation, ranging from $150.0 Million to $350.0 Million.

**Q: What is the projected valuation for the Healthcare Providers client type in the US preimplantation genetic-testing market?**
A: The projected valuation for Healthcare Providers is between $180.0 Million and $380.0 Million.

**Q: What end-use segment is anticipated to dominate the US preimplantation genetic-testing market?**
A: Fertility Clinics are anticipated to dominate, with a valuation range of $180.0 Million to $380.0 Million.

**Q: How does the US preimplantation genetic-testing market compare to other segments in terms of growth?**
A: The market appears to be on a growth trajectory, with a projected increase to $950.0 Million by 2035, indicating robust demand.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-preimplantation-genetic-testing-market-14610*